Haemonetics (HAE) Tops Q3 EPS by 18c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.94, $0.18 better than the analyst estimate of $0.76. Revenue for the quarter came in at $259 million versus the consensus estimate of $255.4 million.
GUIDANCE:
Haemonetics sees FY2020 EPS of $3.30-$3.40, versus the consensus of $3.18.
For earnings history and earnings-related data on Haemonetics (HAE) click here.